Pfizer agrees with U.S. Government on discounted drug costs

Pfizer Inc. announced a significant agreement with the U.S. Government aimed at reducing prescription drug prices for American patients. The deal also seeks to strengthen the United States' position as a global leader in biopharmaceutical innovation.

Under the voluntary agreement, Pfizer will implement measures to ensure Americans receive drug prices comparable to those in other developed countries. The company will also participate in the TrumpRx.gov platform, allowing American patients to purchase Pfizer medicines at substantial discounts. The majority of Pfizer's primary care treatments and select specialty brands will be offered at savings potentially reaching 85%, with an average discount of 50%.

Pfizer CEO Albert Bourla stated the agreement is a "win for American patients, a win for American leadership, and a win for Pfizer." He emphasized that the agreement lowers costs for patients and enables increased investment in the U.S. biopharmaceutical ecosystem, ending a situation where American families disproportionately bore the cost of innovation. Bourla added that the deal provides certainty regarding tariffs and pricing, which had suppressed industry valuations.

With this agreement, Pfizer intends to focus on developing next-generation cures, particularly in oncology, obesity, vaccines, and inflammation and immunology. The company committed to investing an additional $70 billion in U.S. research, development, and capital projects over the next few years. This supplements over $83 billion invested in American biotech innovation from 2018 to 2024.